News Despite study bust, Vistagen still hopes to file anxiety dru... Vistagen has chalked up another trial failure for fasedienol, its drug candidate for social anxiety disorder.
News PMV cues up filing for first p53-directed cancer therapy PMV is preparing to file for approval of its first-in-class oral p53 protein reactivator, rezatopopt, for ovarian cancer in the first quarter of 2027.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
